LuciSelin — Selinexor 20 mg, 32 pcs, Lucius

LuciSelin — Selinexor Tablets 20 mg, 32 Tablets

Product code: 513

53640₴ 58468₴ -8% On order · from 10 days

Analogues

LuciSelin Selinex
1
Active ingredient
Dosage form Tablets
Tablets per pack 32

LuciSelin is an innovative targeted antineoplastic agent representing a first-in-class selective inhibitor of nuclear export (SINE). The active pharmaceutical ingredient is selinexor at a strength of 20 mg supplied as film-coated oral tablets (Selinexor Tablets 20 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Selinexor selectively blocks exportin-1 (XPO1), a protein responsible for transporting tumor suppressor proteins (such as p53, Rb, FoxO), kinases, and growth factors from the cell nucleus to the cytoplasm. Inhibition of XPO1 leads to the nuclear accumulation of these tumor suppressors, their reactivation, suppression of tumor cell growth, and induction of apoptosis (programmed cell death). The drug is used in combination or monotherapy for multiple myeloma and diffuse large B-cell lymphoma. The 20 mg strength allows flexible dosing to achieve the required total dose.

Supplied in a package containing 32 tablets of 20 mg (packaged in 4 blister packs of 8 tablets each). Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciSelin 20 mg:

  • ✅ Innovative SINE Mechanism: Selective inhibition of nuclear protein export via XPO1 blockade.
  • ✅ Tumor Suppressor Reactivation: Restoration of p53 and other regulatory proteins inside the cell nucleus to trigger apoptosis.
  • ✅ Efficacy in Refractory Cancers: Assists patients with multiple myeloma resistant to other drug classes.
  • ✅ Convenient Packaging: 32 tablets of 20 mg (4 blisters x 8 pcs.) for precise administration compliance.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Xpovio).

LuciSelin is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Selinexor — 20 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 20 mg strength. Each package contains 32 tablets (4 blister packs of 8 tablets) along with prescribing information. Labeled with LuciSelin (Selinexor Tablets 20 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Selinexor is an oral selective inhibitor of nuclear export (SINE) that covalently binds to and inhibits XPO1 (exportin-1). XPO1 blockade prevents the nuclear export of tumor suppressors, cell cycle regulators, and growth factors. This causes their nuclear accumulation, cell cycle arrest, and apoptosis of tumor cells while minimally affecting normal tissues.

Pharmacokinetics:

  • Absorption: Following oral administration, selinexor is absorbed relatively rapidly; peak plasma concentration (Tmax) is achieved within approximately 2 to 4 hours. Food intake has no clinically significant effect on overall exposure.
  • Distribution: Human plasma protein binding is approximately 95%.
  • Metabolism: Extensively metabolized in the liver, primarily via reduction mediated by aldo-keto reductases, as well as cytochrome P450 oxidation.
  • Elimination: Excreted predominantly via feces and renally as metabolites. Terminal elimination half-life (T1/2) averages approximately 6 to 8 hours.

LuciSelin is indicated in adult patients for:

  • Multiple Myeloma: In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy and whose disease is refractory to multiple anti-myeloma agents. Also in combination with bortezomib and dexamethasone.
  • Diffuse Large B-Cell Lymphoma (DLBCL): Treatment of adult patients with relapsed or refractory DLBCL after at least two lines of systemic therapy.

LuciSelin is administered orally on scheduled dosing days determined by the treatment regimen (typically once weekly on specific days of the cycle).

Dosing Regimen:
The recommended standard dose for multiple myeloma (in combination with dexamethasone) is 80 mg (four 20 mg tablets) once weekly on the same day of each 28-day cycle. Dose adjustments may be made by the physician based on tolerability.

Administration Guidelines:
Tablets should be swallowed whole with water; do not break, crush, or chew. It is recommended to take the medication after a light meal to reduce the risk of nausea. Anti-emetic and anti-diarrheal medications are frequently prescribed on dosing days to prevent adverse reactions.

Administration of LuciSelin is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to selinexor or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (requiring dosage adjustment).

Selinexor is metabolized via hepatic enzymes and aldo-keto reductases:

  • Strong CYP450 Inducers or Inhibitors: Although the primary metabolic pathway of selinexor is not directly mediated by CYP3A4, caution should be exercised when co-administering strong inducers (rifampicin, phenytoin) or inhibitors.
  • Drugs Causing Nausea, Fatigue, or Weight Loss: Co-administration with such agents may exacerbate gastrointestinal and general adverse events.
  • Anticoagulants and Antiplatelet Agents: Blood coagulation monitoring is required due to the risk of thrombocytopenia.

Pregnancy:
LuciSelin is contraindicated during pregnancy. Based on its mechanism of action, selinexor may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of selinexor into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Nausea, vomiting, diarrhea, decreased appetite, weight loss, constipation, stomatitis. Mandatory prophylactic anti-emetic therapy is required.
  • Hematologic Toxicity: Thrombocytopenia, neutropenia, anemia, leukopenia (routine complete blood count monitoring required).
  • General Disorders: Fatigue, asthenia, muscle weakness, pyrexia, dizziness, confusional state.
  • Metabolic Abnormalities: Hyponatremia, hypokalemia, hyperglycemia.

Symptoms:
Specific acute overdose symptoms of selinexor are unestablished. Anticipated manifestations include exacerbated adverse reactions (severe nausea, vomiting, pronounced fatigue, and hematologic toxicity).

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment and initiate supportive and symptomatic care, including fluid-electrolyte balance correction and blood count support.

Storage Requirements for LuciSelin 20 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister packs. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciSelin 20 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Selinexor Tablets 20 mg, and 32 Tablets (4 blisters x 8 tablets) count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00